Document
Page 1: Introduction to Drug Pricing in the U.S.
High Prices
Americans pay higher prices for brand drugs compared to other industrialized nations.
79% of Americans find U.S. prescription drug prices unreasonable.
Approximately 30% report not taking prescribed medications due to cost.
70% state that lowering drug costs is their top health care priority.
Government Action
Congress and the Biden Administration are considering measures to lower drug prices.
Federal intervention could save money for governments, employers, and consumers but would shift away from market reliance.
U.S. drug companies make an estimated 75% of their profits from American consumers, indicating high prices impact global profit margins.
H.R. 3 Act
The Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3) aims to enable HHS to set drug prices.
Passed the House in late 2019 but stalled in the Senate.
It would authorize HHS to use formulas and negotiations to set prices and impose tax penalties on non-compliant manufacturers.
This act aims to control manufacturer pricing through regulated prices rather than traditional administered prices.
Key Policy Questions
Process for Pricing: What pricing process should HHS use?
Scope of Prices: Should prices be set for only high-cost drugs or include competitive drugs?
Nature of Price: Is the stated price the actual sale price or a ceiling price?
Population Coverage: Will HHS pricing apply broadly (all patients) or narrowly (specific beneficiaries)?
Value Assessment: How will HHS evaluate a drug's value in price determination?
Selection of Drugs: How should HHS choose drugs for pricing?
Page 2: HHS Pricing Process
Authority and Processes
Legislation must clarify actions if negotiations with manufacturers fail.
Approaches to Price Setting
Unilateral Price Setting: HHS directly sets prices without negotiation.
Rulemaking: HHS uses notice and comment rulemaking for transparency.
Independent Arbitrator: Prices set by an arbitrator to mediate disputes when negotiations fail.
Unilateral HHS Authority
HHS could set prices unilaterally, providing minimal procedural requirements.
The Secretary may weigh negotiation input and expert advice.
Rulemaking Approach
Formal rulemaking requires multiple stakeholder inputs based on APA rules.
Proposed prices must be published and open to public comments.
Could streamline the process by shortening comment periods.
Page 3: Regulatory Framework
Regulatory Framework Requirement
New regulations should guide significant pricing decisions and limit arbitrary actions.
HHS Announcements
HHS must indicate proposed drug prices with relevant data in its initial notice.
Final announcements must incorporate public comments, as necessitated by APA.
The White House OMB reviews all proposed pricing actions.
Independent Arbitration
Legislation may define arbitrators and their selection process.
Arbitrators set prices within specified ranges or decide which party's proposed price is binding.
Concerns exist about potential biases of federal arbitrators over private arbitration.
Page 4: Drug Category Classification
Categories of Drugs
Medicines Without Competition: Drugs with market exclusivity and no alternatives.
Medicines with Therapeutic Alternatives: Multiple products available for similar treatments.
Generic Drugs: Competitively priced alternatives to brand drugs.
U.S. Pricing Practices
U.S. allows manufacturers to set prices freely, particularly for non-competitive drugs.
U.S. prices for brand drugs are significantly higher—average 3.5 times OECD nations.
High-cost examples include oncology treatments and orphan drugs.
Page 5: Competition Among Brand Medicines
Competition with Therapeutic Alternatives
Many prescriptions encounter competition among similar treatments.
Limiting HHS pricing for these drugs would impact the number of medicines affected.
Pricing of Hepatitis C Treatments
Hepatitis C breakthrough therapies remain costly despite competition.
Prices are substantially higher in the U.S. compared to OECD countries; examples range widely.
Generic Drug Dynamics
Generics account for a large percentage of prescriptions but contribute less to total spending.
Highly-competitive generic markets may not benefit from regulated price systems.
Page 6: Negotiation and Price Setting
Negotiation Flexibility for Insurers
If prices set by HHS have ceilings, insurers can negotiate lower rates.
This can lead to volume increases and rebates based on strategies to steer patients towards specific drugs.
Discounting and Cost Sharing
Patient cost-sharing often utilizes list prices, not net prices post-rebate, raising costs for patients.
Legislation could link patient payments more closely to true costs after discounts.
Page 7: Scope of Pricing among Patient Populations
Narrow vs. Broad Implementation
Narrow pricing affects Medicare; broader scope impacts all patients.
Broad application would lower costs universally but could deter manufacturing investment.
Rebate Programs
Current rebate-based programs impact overall drug costs and pricing rationality for all payers.
Page 8: Valuation Basis for Drug Pricing
Pricing Based on Foreign Benchmarks
Setting U.S. prices to reflect foreign prices may backlash, raising prices in comparison countries.
Value-Based Pricing
Price determination should assess treatment effectiveness versus costs.
Difficulty arises in defining clear metrics to measure real value and effectiveness in treatments.
Page 9: Conducting Cost-Effectiveness Research
Government's Role
HHS must be the primary entity for conducting price-setting analyses.
A mixed approach of federal employees and external contractors could enhance effectiveness.
Page 10: Price Setting Regulation Capabilities
Importance of Funding
Creating a durable infrastructure for price-setting requires stable funding mechanisms.
Page 11: Drug Selection for Pricing
Selection Criteria
HHS may select drugs posing significant patient savings and with prolonged high prices.
Focusing on low-value treatments enhances overall health outcomes by allowing investment in high-value innovations.